Skip to main page content

Review

. 2021 Jan;141(1):217-221.

doi: 10.1016/j.jid.2020.05.097. Epub 2020 Jun 12.

Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development

Affiliations

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Yale Center for Molecular Discovery, Yale University, New Haven, Connecticut, USA.
³ Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
⁴ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: michael.girardi@yale.edu.

PMID: 32534802
DOI: 10.1016/j.jid.2020.05.097

Free article

Review

Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development

Fatima N Mirza et al. J Invest Dermatol. 2021 Jan.

Free article

. 2021 Jan;141(1):217-221.

doi: 10.1016/j.jid.2020.05.097. Epub 2020 Jun 12.

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Yale Center for Molecular Discovery, Yale University, New Haven, Connecticut, USA.
³ Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
⁴ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: michael.girardi@yale.edu.

PMID: 32534802
DOI: 10.1016/j.jid.2020.05.097

No abstract available

PubMed Disclaimer

Similar articles

Haematological cancer: Resiquimod—a topical CTCL therapy.
Killock D. Killock D. Nat Rev Clin Oncol. 2015 Oct;12(10):563. doi: 10.1038/nrclinonc.2015.142. Epub 2015 Aug 25. Nat Rev Clin Oncol. 2015. PMID: 26305037 No abstract available.
Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M, Gniadecki R. Kamstrup M, et al. Dermatol Clin. 2008 Jan;26 Suppl 1:45-7. Dermatol Clin. 2008. PMID: 18405187 No abstract available.
New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ. Scarisbrick JJ. Curr Opin Oncol. 2016 Sep;28(5):384-9. doi: 10.1097/CCO.0000000000000311. Curr Opin Oncol. 2016. PMID: 27390044 Review.
Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A, Neri N, Fernandez-Diez J, Silva L, Nambo MJ. Aviles A, et al. Hematology. 2015 Oct;20(9):538-42. doi: 10.1179/1607845415Y.0000000002. Epub 2015 Jan 16. Hematology. 2015. PMID: 25592781 Clinical Trial.
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S, Zhang C, Duvic M. Rangwala S, et al. Future Med Chem. 2012 Mar;4(4):471-86. doi: 10.4155/fmc.12.6. Future Med Chem. 2012. PMID: 22416775 Review.

See all similar articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

TL1 TR001864/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information